稳定期COPD患者血清suPAR、IL-8、MMP-9的水平及其意义

doi:10.3969/j.issn.1000-8535.2018.02.013

广州医药 ›› 2018, Vol. 49 ›› Issue (2): 50-53.DOI: 10.3969/j.issn.1000-8535.2018.02.013

稳定期COPD患者血清suPAR、IL-8、MMP-9的水平及其意义

刘俊¹, 李荣华²

1 广州医科大学附属广州市第一人民医院呼吸内科(广州 510180)
2 广州医科大学护理学院(广州 510180)

收稿日期:2017-11-25 出版日期:2018-03-20 发布日期:2021-12-01
通讯作者: 李荣华,E-mail:sunnylirh@163.com
基金资助:
广州市属高校科研项目(1201430811);广州医科大学科学科研项目(2014A02)

The level and significance of serum suPAR, IL-8 and MMP-9 in patients with stable chronic obstructive pulmonary disease

LIU Jun¹, LI Ronghua²

1 Department of Respiratory, the First People's Hospital affiliated to Guangzhou Medical University, Guangzhou 510180, China
2 School of Nursing, Guangzhou Medical University, Guangzhou 510080, China

Received:2017-11-25 Online:2018-03-20 Published:2021-12-01

摘要/Abstract

摘要： 目的分析稳定期慢性阻塞性肺疾病患者血浆可溶性尿激酶型纤溶酶原激活因子受体(suPAR)、IL-8和MMP-9的水平,探讨其在慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)患者中的临床意义。方法入选60例稳定期COPD患者设为观察组,再根据肺功能分为Ⅱ级、Ⅲ级及Ⅳ级亚组;同时选取同期健康体检者70例作为对照组,检测两组的血清suPAR、IL-8和MMP-9水平及肺功能,比较观察组跟对照之间的差异,同时比较Ⅱ级、Ⅲ级、Ⅳ级亚组及对照组之间的差异。结果观察组血清suPAR、IL-8和MMP-9水平高于对照组;Ⅱ级、Ⅲ级及Ⅳ级各亚组的血清suPAR、IL-8和MMP-9均高于对照组;Ⅲ级及Ⅳ级组高于Ⅱ级组;以上差异均有统计学意义(P<0.05)。但Ⅲ级与Ⅳ级比较无差异(P>0.05)。结论血清suPAR、IL-8和MMP-9在稳定期COPD患者中水平增高,且反映了其严重程度,有望成为COPD病情评估新指标及未来分子水平治疗的新靶点。

关键词: 慢性阻塞性肺疾病, 稳定期, 可溶性尿激酶型纤溶酶原激活因子受体, 白介素-8, 基质金属蛋白酶-9

Abstract: Objective To analyze the serum soluble urokinase-type plasminogen activator receptor, IL-8 and MMP-9 levels in stable chronic obstructive pulmonary disease and explore its clinical significance.Methods 60 patitents with stable COPD were selected as the observation group, and subdivided to subgroups stage Ⅱ, Ⅲ and Ⅳ. Meanwhile, 70 healthy individuals were enrolled as the control group. And then suPAR、IL-8 and MMP-9 levels and pulmonary function were measured in both groups. The differences between both groups as well as all the subgroups were compared.Results The suPAR level of the observation group was higher than that of the control group. Also, compared with the control group, stage Ⅱ, Ⅲ and Ⅳ subgroups showed much higher level of suPAR,IL-8,MMP-9. And it was higher in stageⅢand Ⅳthan in stageⅡ. However, there was no difference between Stage Ⅲ and Ⅳ.Conclusion The suPAR,IL-8 and MMP-9 level are higher in COPD patients and are related to the severity of stages. Therefore, it could be an appropriate biomarker as well as a novel target for future therapy and further evaluation.

Key words: Chronic obstructive pulmonary disease(COPD), Stable, SuPAR, IL-8, MMP-9

刘俊, 李荣华. 稳定期COPD患者血清suPAR、IL-8、MMP-9的水平及其意义[J]. 广州医药, 2018, 49(2): 50-53.

LIU Jun, LI Ronghua. The level and significance of serum suPAR, IL-8 and MMP-9 in patients with stable chronic obstructive pulmonary disease[J]. Guangzhou Medical Journal, 2018, 49(2): 50-53.

参考文献

[1] VOGELMEIER C F, CRINER G J, MARTINEZ J, et al.Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease 2017 report[EB/OL].(2016-11-16)[2016-12-09].http://goldcopd.org/
[2] 中华医学会呼吸病学分会,慢性阻塞性肺疾病诊治指南[J].中华结核和呼吸杂志,2013,36(4):255-264.
[3] SIN D D, MAN S F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease[J].Circulation,2003,107(11):1514-1519.
[4] de TORRES J P, PINTO-PLATA V, CASANOVA C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD[J]. Chest, 2008, 133(6):1336-1343.
[5] OWEN C A. Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis, 2008, 3(2):253-268.
[6] RAGNO P. The urokinase receptor: a ligand or areceptor? Story of a sociable molecule[J]. Cell Mol Life, 2006, 63(9):1028-1037.
[7] TUNC T, CEKMEZ F, YILDIRIM S, et al. Predictive value of soluble urokinase plasminogen activator receptor, soluble ST2, and IL-33 in bronchopulmonary dysplasia[J]. Pediatr Res, 2014,75(6):788-792.
[8] PORTELLI M A, SIEDLINSKI M, STEWART C E, et al. Genome mapping identifies human plasma kallikrein as a post translational regulator of serum uPAR levels[J]. FASEB J, 2014, 28(2):923-934.
[9] SHINKAI M,GREGORY H F,BRUCE K R. Macrolide antibiotics modulate ERK phosphorulation and IL-8 and GM-CSF production by human bronchial epithelial cells[J]. Am J Physiol Lung Cell Mol Physiol, 2006,290(1):75-85.
[10] 于寰,张朝阳,范丽,等.COPD小气道重塑的HRCT研究及与肺功能的相关性[J]. 临床放射学杂志,2013,32(7):943-946.
[11] MEUNIER I, EMBURY-HYATT C,STEBNER S, et al. Virulence differences of closely related pandemic 2009 H1N1 isolates correlate with increased inflammatory reponses in ferrets[J]. Virology, 2011,410(3):667-669.
[12] BEAUFORT N, LEDUC D, EGUCHI H, et al. The human airway trypsin-like protease modulates the urokinase receptor (uPAR, CD87) structure and functions[J]. Am J Physiol Lung Cell Mol Physiol, 2007,292(5): 1263-1272.
[13] MONTUORI N, SELLERI C, RAGNO P. The urokinase-receptor in infectious diseases[J]. Infez Med, 2012, 20:13-18.
[14] BARNES P J. The cytokine network in asthma and chronic obstructive pulmonary disease[J]. J Clin Invest, 2008, 118(11):3546-3556.
[15] DONNELLY L E, BARNES P J. Chemokine receptors as therapeutic targets in Chronic obstructive disease[J]. Trends Pharmacol Sci, 2006,27:546-553.
[16] RIISBRO R, CHRISTENSEN I J, HØGDALL C, et al. Solubleurokinase plasminogen activator receptor measurements: influence of sample handling[J]. Int J Biol Markers, 2001,16(4):233-239.
[17] ANDERSEN O, EUGEN-OLSEN J, KOFOED K, et al. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy[J]. J Med Virol, 2008,80(2): 209-216.
[18] 刘揆亮,吴静. 尿激酶型纤溶酶原激活物受体及可溶性尿激酶型纤溶酶原激活物受体与炎症相关的研究进展[J]. 临床与病理杂志,2014,34(4):425-430.
[19] WANG Q, WANG Y, ZHANG Y, et al. The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease[J]. Respir Res, 2013,14(1):67.
[20] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中国医学前沿杂志(电子版),2014,(6)2:67-80.

稳定期COPD患者血清suPAR、IL-8、MMP-9的水平及其意义

The level and significance of serum suPAR, IL-8 and MMP-9 in patients with stable chronic obstructive pulmonary disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	罗艳慧, 唐映莲, 罗巧娟, 欧阳莲芳, 关小娟. 集体呼吸操对慢阻肺稳定期患者的执行率影响研究[J]. 广州医药, 2021, 52(1): 77-80.
[2]	卢心鹏, 廖东江, 罗钰龙, 潘俊辉, 陈鸿生, 王峰. iTRAQ联合质谱技术筛选COPD大鼠肺组织差异表达蛋白[J]. 广州医药, 2020, 51(6): 6-10.
[3]	李晓岩, 陈豫钦, 莫泽珣, 何桦, 张歆, 唐万娜, 谭锦文. 能倍乐对合并前列腺肥大的慢性阻塞性肺疾病急性加重的影响[J]. 广州医药, 2020, 51(3): 73-76.
[4]	曾映雪. 全程介入护理对慢性阻塞性肺疾病和哮喘患者管理的治疗效果观察[J]. 广州医药, 2018, 49(6): 121-123.
[5]	郑翠环, 李婷, 张少珍, 魏彩红, 黄明生. 护理干预在慢性阻塞性肺疾病患者中的效果[J]. 广州医药, 2018, 49(4): 47-50.
[6]	马程远, 关键, 张中宏, 梁文晋, 任侠, 王耀林. HHIP基因rs13118928、rs13141461与新疆蒙古族慢性阻塞性肺疾病易感性的相关性研究[J]. 广州医药, 2018, 49(2): 1-5.
[7]	萧鲲, 林虹, 杨婉瑜, 朱丽娟, 许浦生. 载脂蛋白E基因多态性在慢性阻塞性肺疾病合并阿尔茨海默病患者中的分布和意义[J]. 广州医药, 2018, 49(2): 84-90.
[8]	侯达繁, 黄方, 于世平, 谭永清, 骆嘉杰, 袁清妹. 八段锦联合呼吸训练对社区慢性阻塞性肺疾病患者疗效研究[J]. 广州医药, 2017, 48(6): 29-32.
[9]	谭杰, 康艳虹, 苏燕娜, 马为. 慢性阻塞性肺疾病急性加重期患者血清PCT、IL-6、hs-CRP水平与肺功能的相关性研究[J]. 广州医药, 2017, 48(3): 93-95.
[10]	宋俏莉, 韩宇娟, 周承志, 梁杰聪. 吸烟对稳定期COPD患者炎症反应和肺功能的影响[J]. 广州医药, 2017, 48(2): 87-88.
[11]	罗秋平. 慢性阻塞性肺疾病稳定期患者自我管理干预疗效分析[J]. 广州医药, 2016, 47(3): 83-84.
[12]	梁锦泉, 周清霞, 李活乾. 支纤镜吸痰及镜下注药治疗COPD的临床研究[J]. 广州医药, 2016, 47(1): 33-34.
[13]	江国杰, 赵菊香, 叶珍珍. 药学服务对门诊中老年COPD患者用药依从性的影响[J]. 广州医药, 2016, 47(1): 41-43.
[14]	陈淑娴, 廖立斌, 朱海平, 何惠光, 林汉生, 万丽梅. 呼吸康复治疗对农村地区COPD稳定期患者BODE评分系统的影响[J]. 广州医药, 2015, 46(6): 38-40.
[15]	李文礼, 蓝光军, 邱清标. 序贯通气治疗慢性阻塞性肺疾病急性加重并II型呼吸衰竭的疗效分析[J]. 广州医药, 2015, 46(6): 70-71.